Keep up with venture capital funding activity in the Seattle area with recent news from three local startups. The companies—Blokable, Zenoti Software, and PTO Exchange—are developing software and other tech-enabled products for three very different industries: housing, spas, and finance. Read... Read more »
[Updated 8/26/19, 10:30am. See below.] Remember when the new wave of expensive cholesterol-lowering drugs—known as PCSK9 inhibitors—was supposed to give the healthcare system a financial heart attack?
Far from it. Four years after approval the two PCSK9 blockers... Read more »
The increasing popularity of Amazon’s annual Prime Day, Cyber Monday, and other online shopping-themed occasions is one of many indicators more Americans are relying on mobile devices and computers, not malls, to shop.
It’s no secret the so-called “Amazon effect,” a... Read more »
An experimental GlaxoSmithKline treatment for multiple myeloma has achieved the main goal of a key study, and the drug maker plans to file for regulatory approval by the end of this year.
GlaxoSmithKline (NYSE: GSK) said Friday that treatment with... Read more »
Biotech news tends to slow down in August but the past seven days have been busy for regulatory decisions. Three drugs and two devices won FDA nods.
Not all companies were as fortunate. Several biotechs reported failed clinical trials or unfavorable... Read more »
About 15 percent of adults in the US, around 37 million people, are estimated to have chronic kidney disease, according to the Centers for Disease Control. They have very few therapeutic options and often progress to kidney failure, which is treatable... Read more »
Ford subsidiary Autonomic today announced a step forward in its drive to expand the online mobility hub it built to manage digital interactions among cars, drivers, fleets, service providers, and auto manufacturers—including Ford’s rivals.
Palo Alto, CA-based Autonomic signed up Ayro... Read more »
Ally, a startup developing software to help businesses chart strategies and track progress toward meeting goals, announced Monday it has raised $8 million from investors to support the Bellevue, WA-based company’s growth.
Palo Alto, CA-based Accel led the Series A... Read more »
We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7 billion in 2018, and Novartis reportedly... Read more »